Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response

David H. Dockrell, Gregory A. Poland, James M. Steckelberg, Peter C. Wollan, Scott R. Strickland, Claire Pomeroy

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

HIV-seropositive adults may be at increased risk of infection due to Haemophilus influenzae type b (Hib) as compared with HIV-seronegative adults. Protein conjugate vaccines have been demonstrated to induce protective levels of antibodies against Hib in immunocompetent infants and also in HIV- seropositive infants. In this study we determined the immunogenicity of three protein conjugate Hib vaccines (PRP-D, HbOC, HbNOMP) in 135 HIV-seropositive adults who received one dose of Hib vaccine. Anti-polyribosylribitol phosphate (PRP) antibodies were measured at 0, 1, 3 and 12 months postimmunization by the Farr method. We demonstrate that all three vaccines are highly immunogenic and result in protective (> 1.0 μg/ml) levels of antibody. Overall the anti-PRP antibody level was > 1.0 μg/ml in 26% of patients preimmunization, 91% at both 1 and 3 months, and 79% at 12 months postvaccination. Comparison of responses to the three vaccines over time demonstrated differences in the mean geometric anti-PRP antibody level at 1 month (p = 0.03) and the 12 month time points (p = 0.03) with lower geometric mean levels in the HbNOMP group, though baseline differences in groups limit the interpretation of these findings. In a univariate analysis of baseline characteristics which predicted poor vaccine response, low total IgG2 levels preimmunization predicted a poor antibody response at 1 month (p < 0.01) and at 12 months (p=0.05), while low CD4 T-cell count predicted poor response at 12 months (p < 0.01). We conclude that all three US licensed protein conjugate Hib vaccines are immunogenic in HIV-seropositive adults, and that baseline CD4 T-cell count and IgG2 levels predict the likelihood of antibody response to vaccine.

Original languageEnglish (US)
Pages (from-to)2779-2785
Number of pages7
JournalVaccine
Volume17
Issue number22
DOIs
StatePublished - Jul 16 1999

Fingerprint

Haemophilus influenzae type b
Haemophilus influenzae
Conjugate Vaccines
Haemophilus Vaccines
Vaccines
immune response
HIV
vaccines
Phosphates
Antibodies
antibodies
CD4 Lymphocyte Count
Proteins
proteins
Antibody Formation
phosphates
Immunoglobulin G
T-Lymphocytes
T-lymphocytes
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases

Cite this

Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. / Dockrell, David H.; Poland, Gregory A.; Steckelberg, James M.; Wollan, Peter C.; Strickland, Scott R.; Pomeroy, Claire.

In: Vaccine, Vol. 17, No. 22, 16.07.1999, p. 2779-2785.

Research output: Contribution to journalArticle

Dockrell, David H. ; Poland, Gregory A. ; Steckelberg, James M. ; Wollan, Peter C. ; Strickland, Scott R. ; Pomeroy, Claire. / Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. In: Vaccine. 1999 ; Vol. 17, No. 22. pp. 2779-2785.
@article{5816b910a3634ae699d6997e18f079b3,
title = "Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response",
abstract = "HIV-seropositive adults may be at increased risk of infection due to Haemophilus influenzae type b (Hib) as compared with HIV-seronegative adults. Protein conjugate vaccines have been demonstrated to induce protective levels of antibodies against Hib in immunocompetent infants and also in HIV- seropositive infants. In this study we determined the immunogenicity of three protein conjugate Hib vaccines (PRP-D, HbOC, HbNOMP) in 135 HIV-seropositive adults who received one dose of Hib vaccine. Anti-polyribosylribitol phosphate (PRP) antibodies were measured at 0, 1, 3 and 12 months postimmunization by the Farr method. We demonstrate that all three vaccines are highly immunogenic and result in protective (> 1.0 μg/ml) levels of antibody. Overall the anti-PRP antibody level was > 1.0 μg/ml in 26{\%} of patients preimmunization, 91{\%} at both 1 and 3 months, and 79{\%} at 12 months postvaccination. Comparison of responses to the three vaccines over time demonstrated differences in the mean geometric anti-PRP antibody level at 1 month (p = 0.03) and the 12 month time points (p = 0.03) with lower geometric mean levels in the HbNOMP group, though baseline differences in groups limit the interpretation of these findings. In a univariate analysis of baseline characteristics which predicted poor vaccine response, low total IgG2 levels preimmunization predicted a poor antibody response at 1 month (p < 0.01) and at 12 months (p=0.05), while low CD4 T-cell count predicted poor response at 12 months (p < 0.01). We conclude that all three US licensed protein conjugate Hib vaccines are immunogenic in HIV-seropositive adults, and that baseline CD4 T-cell count and IgG2 levels predict the likelihood of antibody response to vaccine.",
author = "Dockrell, {David H.} and Poland, {Gregory A.} and Steckelberg, {James M.} and Wollan, {Peter C.} and Strickland, {Scott R.} and Claire Pomeroy",
year = "1999",
month = "7",
day = "16",
doi = "10.1016/S0264-410X(99)00089-4",
language = "English (US)",
volume = "17",
pages = "2779--2785",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response

AU - Dockrell, David H.

AU - Poland, Gregory A.

AU - Steckelberg, James M.

AU - Wollan, Peter C.

AU - Strickland, Scott R.

AU - Pomeroy, Claire

PY - 1999/7/16

Y1 - 1999/7/16

N2 - HIV-seropositive adults may be at increased risk of infection due to Haemophilus influenzae type b (Hib) as compared with HIV-seronegative adults. Protein conjugate vaccines have been demonstrated to induce protective levels of antibodies against Hib in immunocompetent infants and also in HIV- seropositive infants. In this study we determined the immunogenicity of three protein conjugate Hib vaccines (PRP-D, HbOC, HbNOMP) in 135 HIV-seropositive adults who received one dose of Hib vaccine. Anti-polyribosylribitol phosphate (PRP) antibodies were measured at 0, 1, 3 and 12 months postimmunization by the Farr method. We demonstrate that all three vaccines are highly immunogenic and result in protective (> 1.0 μg/ml) levels of antibody. Overall the anti-PRP antibody level was > 1.0 μg/ml in 26% of patients preimmunization, 91% at both 1 and 3 months, and 79% at 12 months postvaccination. Comparison of responses to the three vaccines over time demonstrated differences in the mean geometric anti-PRP antibody level at 1 month (p = 0.03) and the 12 month time points (p = 0.03) with lower geometric mean levels in the HbNOMP group, though baseline differences in groups limit the interpretation of these findings. In a univariate analysis of baseline characteristics which predicted poor vaccine response, low total IgG2 levels preimmunization predicted a poor antibody response at 1 month (p < 0.01) and at 12 months (p=0.05), while low CD4 T-cell count predicted poor response at 12 months (p < 0.01). We conclude that all three US licensed protein conjugate Hib vaccines are immunogenic in HIV-seropositive adults, and that baseline CD4 T-cell count and IgG2 levels predict the likelihood of antibody response to vaccine.

AB - HIV-seropositive adults may be at increased risk of infection due to Haemophilus influenzae type b (Hib) as compared with HIV-seronegative adults. Protein conjugate vaccines have been demonstrated to induce protective levels of antibodies against Hib in immunocompetent infants and also in HIV- seropositive infants. In this study we determined the immunogenicity of three protein conjugate Hib vaccines (PRP-D, HbOC, HbNOMP) in 135 HIV-seropositive adults who received one dose of Hib vaccine. Anti-polyribosylribitol phosphate (PRP) antibodies were measured at 0, 1, 3 and 12 months postimmunization by the Farr method. We demonstrate that all three vaccines are highly immunogenic and result in protective (> 1.0 μg/ml) levels of antibody. Overall the anti-PRP antibody level was > 1.0 μg/ml in 26% of patients preimmunization, 91% at both 1 and 3 months, and 79% at 12 months postvaccination. Comparison of responses to the three vaccines over time demonstrated differences in the mean geometric anti-PRP antibody level at 1 month (p = 0.03) and the 12 month time points (p = 0.03) with lower geometric mean levels in the HbNOMP group, though baseline differences in groups limit the interpretation of these findings. In a univariate analysis of baseline characteristics which predicted poor vaccine response, low total IgG2 levels preimmunization predicted a poor antibody response at 1 month (p < 0.01) and at 12 months (p=0.05), while low CD4 T-cell count predicted poor response at 12 months (p < 0.01). We conclude that all three US licensed protein conjugate Hib vaccines are immunogenic in HIV-seropositive adults, and that baseline CD4 T-cell count and IgG2 levels predict the likelihood of antibody response to vaccine.

UR - http://www.scopus.com/inward/record.url?scp=0033575488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033575488&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00089-4

DO - 10.1016/S0264-410X(99)00089-4

M3 - Article

VL - 17

SP - 2779

EP - 2785

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -